Sensorion Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
66
- Stock Symbol
-
ALSEN
- Share Price
-
$9.54
- (As of Thursday Closing)
Sensorion General Information
Description
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
Contact Information
Website
www.sensorion.comCorporate Office
- 375 rue du Professeur Joseph Blayac
- 34080 Montpellier
- France
Corporate Office
- 375 rue du Professeur Joseph Blayac
- 34080 Montpellier
- France
Sensorion Timeline
Sensorion Stock Performance
As of 12-Nov-2026, Sensorion’s stock price is $9.54. Its current market cap is $98.4M with 10.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.54 | $9.25 | $5.88 - $46.54 | $98.4M | 10.3M | 17.9K | -$5.24 |
Sensorion Financials Summary
As of 30-Jun-2026, Sensorion has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 86,387 | 53,888 | 110,256 | 76,509 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (40,658) | (33,207) | (29,556) | (23,168) |
| Net Income | (39,809) | (33,196) | (28,104) | (23,874) |
| Total Assets | 115,066 | 67,995 | 92,899 | 51,403 |
| Total Debt | 3,662 | 1,505 | 2,290 | 3,176 |
Sensorion Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sensorion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sensorion Comparisons
Industry
Financing
Details
Sensorion Competitors (6)
One of Sensorion’s 6 competitors is Lite Strategy, a Corporation company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lite Strategy | Corporation | San Diego, CA | ||||
| Rinri Therapeutics | Venture Capital-Backed | Sheffield, United Kingdom | ||||
| Lyra Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Autifony Therapeutics | Formerly VC-backed | Stevenage, United Kingdom | ||||
| Audion Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands |
Sensorion Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sensorion Patents
Sensorion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026062170-A1 | Azasetron for the prevention of hearing loss in subjects receiving cisplatin | Pending | 19-Sep-2024 | ||
| AU-2024288814-A1 | Intra cochlear administration device | Pending | 13-Jul-2023 | ||
| EP-4743042-A1 | Intra cochlear administration device | Pending | 13-Jul-2023 | ||
| WO-2025012472-A1 | Intra cochlear administration device | Inactive | 13-Jul-2023 | ||
| AU-2024290039-A1 | Azasetron for the preservation of residual hearing following cochlear implantation | Pending | 03-Jul-2023 | A61K31/538 |
Sensorion Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sensorion Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sensorion ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Sensorion FAQs
-
When was Sensorion founded?
Sensorion was founded in 2009.
-
Where is Sensorion headquartered?
Sensorion is headquartered in Montpellier, France.
-
What is the size of Sensorion?
Sensorion has 66 total employees.
-
What industry is Sensorion in?
Sensorion’s primary industry is Biotechnology.
-
Is Sensorion a private or public company?
Sensorion is a Public company.
-
What is Sensorion’s stock symbol?
The ticker symbol for Sensorion is ALSEN.
-
What is the current stock price of Sensorion?
As of 12-Nov-2026 the stock price of Sensorion is $9.54.
-
What is the current market cap of Sensorion?
The current market capitalization of Sensorion is $98.4M.
-
Who are Sensorion’s competitors?
Lite Strategy, Rinri Therapeutics, Lyra Therapeutics, Autifony Therapeutics, and Audion Therapeutics are some of the 6 competitors of Sensorion.
-
What is Sensorion’s annual earnings per share (EPS)?
Sensorion’s EPS for 12 months was -$5.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
